These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 24175724)

  • 1. Antiangiogenic therapy for high-grade gliomas: current concepts and limitations.
    De Bonis P; Marziali G; Vigo V; Peraio S; Pompucci A; Anile C; Mangiola A
    Expert Rev Neurother; 2013 Nov; 13(11):1263-70. PubMed ID: 24175724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-angiogenic approaches to malignant gliomas.
    Soffietti R; Trevisan E; Bertero L; Bosa C; Ruda R
    Curr Cancer Drug Targets; 2012 Mar; 12(3):279-88. PubMed ID: 22229250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiogenic inhibition in high-grade gliomas: past, present and future.
    Jo J; Schiff D; Purow B
    Expert Rev Neurother; 2012 Jun; 12(6):733-47. PubMed ID: 22650175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bevacizumab-based therapy in relapsed glioblastoma: rationale and clinical experience to date.
    Chinot OL
    Expert Rev Anticancer Ther; 2012 Nov; 12(11):1413-27. PubMed ID: 23249106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolving strategies: future treatment of glioblastoma.
    Chamberlain M
    Expert Rev Neurother; 2011 Apr; 11(4):519-32. PubMed ID: 21469925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primetime for antiangiogenic therapy.
    Tabatabai G; Stupp R
    Curr Opin Neurol; 2009 Dec; 22(6):639-44. PubMed ID: 19786873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bevacizumab in the treatment of high-grade gliomas: an overview.
    Kunnakkat S; Narayana A
    Angiogenesis; 2011 Dec; 14(4):423-30. PubMed ID: 21858651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiogenesis and anti-angiogenic molecularly targeted therapies in malignant gliomas.
    Argyriou AA; Giannopoulou E; Kalofonos HP
    Oncology; 2009; 77(1):1-11. PubMed ID: 19439998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Signal transduction inhibitors and antiangiogenic therapies for malignant glioma.
    Mellinghoff IK; Lassman AB; Wen PY
    Glia; 2011 Aug; 59(8):1205-12. PubMed ID: 21351155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of all‑trans retinoic acid on VEGF and HIF‑1α expression in glioma cells under normoxia and hypoxia and its anti‑angiogenic effect in an intracerebral glioma model.
    Liang C; Guo S; Yang L
    Mol Med Rep; 2014 Nov; 10(5):2713-9. PubMed ID: 25201493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiangiogenic therapy in malignant glioma: promise and challenge.
    Sathornsumetee S; Rich JN
    Curr Pharm Des; 2007; 13(35):3545-58. PubMed ID: 18220791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiangiogenic Therapy of High-Grade Gliomas.
    Jo J; Wen PY
    Prog Neurol Surg; 2018; 31():180-199. PubMed ID: 29393186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiangiogenic therapy in malignant gliomas.
    Norden AD; Drappatz J; Wen PY
    Curr Opin Oncol; 2008 Nov; 20(6):652-61. PubMed ID: 18841047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors.
    Folkins C; Man S; Xu P; Shaked Y; Hicklin DJ; Kerbel RS
    Cancer Res; 2007 Apr; 67(8):3560-4. PubMed ID: 17440065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current standards and new concepts in MRI and PET response assessment of antiangiogenic therapies in high-grade glioma patients.
    Hutterer M; Hattingen E; Palm C; Proescholdt MA; Hau P
    Neuro Oncol; 2015 Jun; 17(6):784-800. PubMed ID: 25543124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bevacizumab for the treatment of high-grade glioma.
    Khasraw M; Simeonovic M; Grommes C
    Expert Opin Biol Ther; 2012 Aug; 12(8):1101-11. PubMed ID: 22663137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiangiogenesis agents avastin and erbitux enhance the efficacy of photodynamic therapy in a murine bladder tumor model.
    Bhuvaneswari R; Yuen GY; Chee SK; Olivo M
    Lasers Surg Med; 2011 Sep; 43(7):651-62. PubMed ID: 22057493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Re: angiogenesis and antiangiogenic therapy for malignant gliomas.
    Kepes JJ
    Brain Tumor Pathol; 2005; 22(1):51. PubMed ID: 18095105
    [No Abstract]   [Full Text] [Related]  

  • 19. [Anti-angiogenesis treatment for brain tumors: present and future].
    Takano S; Matsumura A
    No Shinkei Geka; 2006 Jul; 34(7):657-78. PubMed ID: 16841703
    [No Abstract]   [Full Text] [Related]  

  • 20. Longitudinal brain imaging of five malignant glioma patients treated with bevacizumab using susceptibility-weighted magnetic resonance imaging at 7 T.
    Grabner G; Nöbauer I; Elandt K; Kronnerwetter C; Woehrer A; Marosi C; Prayer D; Trattnig S; Preusser M
    Magn Reson Imaging; 2012 Jan; 30(1):139-47. PubMed ID: 21982163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.